Uptake in the salivary glands is the dose-limiting factor during endoradiotherapy with small-molecule PSMA inhibitors, resulting in (partially reversible) xerostomia when applied with 177Lu, and severe to persistent xerostomia when applied with 225Ac [50,51]. The gene discussed is FOLH1; the disease is xerostomia.